Efficacy of Ustekinumab (Anti-IL_12/23) followed by Abatcept (CTLA4-lg) for the tretment of Psoriasis Vulgaris

Project: Research project

Description

The primary objective of the study is to determine whether co-stimulatory blockade with abatacept (CTLA4Ig) will induce tolerance and prevent relapses after medication has been discontinued in psoriasis vulgaris when administered following a decrease in the inflammatory response induced with ustekinumab (anti-IL-12/23).
StatusFinished
Effective start/end date9/1/1410/31/18

Funding

  • Benaroya Research Institute at Virginia Mason (FY18ITN093//5UM1AI109565-05)
  • National Institute of Allergy and Infectious Diseases (FY18ITN093//5UM1AI109565-05)

Fingerprint

Interleukin-23
Interleukin-12
Psoriasis
Recurrence
Ustekinumab
Abatacept